NICE approves eltrombopag for NHS use

NICE has ruled that eltrombopag (Revolade) can be considered for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) within its marketing authorisation, following a review of its 2010 guidance.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes | SCIENCE PHOTO LIBRARY
Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes | SCIENCE PHOTO LIBRARY

To be eligible for treatment, the patient must either be refractory to standard active treatments and rescue therapies or have severe ITP and a high risk of bleeding that needs frequent course of rescue therapies. 

The NICE recommendations are made on the proviso that the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.

View Revolade drug record

NICE guidance on eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205).

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: azathioprine.
Use our constantly updated...

New MIMS section offers external resources to benefit your practice

New MIMS section offers external resources to benefit your practice

MIMS Hosted is a new section of the MIMS website providing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

New headache toolkit offers tips to improve management in primary care

New headache toolkit offers tips to improve management in primary care

GPs should use standardised headache assessment criteria...